Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and toll-like receptor activation

Infection and Immunity

Volumn 76, Issue 9, 2008, Pages 4183-4189

  Hellerud, Bernt Christian ^a,b   Stenvik, Jørgen ^c   Espevik, Terje ^c   Lambris, John D ^d   Mollnes, Tom Eirik ^b   Brandtzaeg, Petter ^a,e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN MD 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; BLOOD ANALYSIS; BLOOD SAMPLING; CELL STRAIN HEK293; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CYTOKINE RELEASE; EMBRYO; HUMAN; HUMAN CELL; INCUBATION TIME; INNATE IMMUNITY; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

EID: 51949103021     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00195-08     Document Type: Article

References (39)

1. Akashi, S., S. Saitoh, Y. Wakahayashi, T. Kikuchi, N. Takamura, Y. Nagai, Y. Kusumoto, K. Fukase, S. Kusumoto, Y. Adachi, A. Kosugi, and K. Miyake. 2003. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198: 1035-1042.
2. Bjerre, A., B. Brusletto, T. E. Mollnes, E. Fritzsonn, E. Rosenqvist, E. Wedege, E. Namork, P. Kierulf, and P. Brandtzaeg. 2002. Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant. J. Infect. Dis. 185:220-228.
3. Brandtzaeg, P. 2006. Pathogenesis and pathophysiology of meningococcal disease, p. 427-480. In M. Frosch and M. Maiden (ed.), Handbook of meningococcal disease. Wiley-VCH Verlag, Weinheim, Germany.
4. Brandtzaeg, P., K. Bryn, P. Kierulf, R. Ovstebo, E. Namork, B. Aase, and E. Jantzen. 1992. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J. Clin. Investig. 89:816-823.
5. Brandtzaeg, P., P. Kierulf, P. Gaustad, A. Skulberg, J. N. Bruun, S. Halvorsen, and E. Sorensen. 1989. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J. Infect. Dis. 159:195-204.
6. Brandtzaeg, P., T. E. Mollnes, and P. Kierulf. 1989. Complement activation and endotoxin levels in systemic meningococcal disease. J. Infect. Dis. 160: 58-65.
7. Brandtzaeg, P., R. Ovstebo, and P. Kierulf. 1992. Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J. Infect. Dis. 166:650-652.
8. Chow, J. C., D. W. Young, D. T. Golenbock, W. J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274:10689-10692.
9. Finch, A. M., A. K. Wong, N. J. Paczkowski, S. K. Wadi, D. J. Craik, D. P. Fairlie, and S. M. Taylor. 1999. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42:1965-1974.
10. Gangloff, S. C., N. Hijiya, A. Haziot, and S. M. Goyert. 1999. Lipopolysaccharide structure influences the macrophage response via CD14-indepen-dent and CD14-dependent pathways. Clin. Infect. Dis. 28:491-496.
11. Gerard, C. 2003. Complement C5a in the sepsis syndrome-too much of a good thing? N. Engl. J. Med. 348:167-169.
12. Hackett, S. J., M. Guiver, J. Marsh, J. A. Sills, A. P. Thomson, E. B. Kaczmarski, and C. A. Hart. 2002. Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch. Dis. Child. 86:44-46.
13. Hackett, S. J., A. P. Thomson, and C. A. Hart. 2001. Cytokines, chemokines and other effector molecules involved in meningococcal disease. J. Med. Microbiol. 50:847-859.
14. Hazelzet, J. A., R. de Groot, G. van Mierlo, K. F. Joosten, A. van der Voort, E. Erenberg, M. H. Suur, W. C. Hop, and C. E. Hack. 1998. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect. Immun. 66:5350-5356.
15. Ingalls, R. R., E. Lien, and D. T. Golenbock. 2000. Differential roles of TLR2 and TLR4 in the host response to gram-negative bacteria: lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J. Endotoxin Res. 6:411-415.
16. Ingalls, R. R., E. Lien, and D. T. Golenbock. 2001. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through Toll-like receptor 2. Infect. Immun. 69:2230-2236.
17. Katragadda, M., P. Magotti, G. Sfyroera, and J. D. Lambris. 2006. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J. Med. Chem. 49:4616-4622.
18. Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13:460-469.
19. Markiewski, M. M., B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28:184-192.
20. Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: immune stimulation by neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 168:1533-1537.
21. Mathew, S., and G. D. Overturf. 2006. Complement and properidin deficiencies in meningococcal disease. Pediatr. Infect. Dis. J. 25:255-256.
22. Mogensen, T. H., S. R. Paludan, M. Kilian, and L. Ostergaard. 2006. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J. Leukoc. Biol. 80:267-277.
23. Moller, A. S., A. Bjerre, B. Brusletto, G. B. Joo, P. Brandtzaeg, and P. Kierulf. 2005. Chemokine patterns in meningococcal disease. J. Infect. Dis. 191:768-775.
24. Mollnes, T. E., T. Lea, S. S. Froland, and M. Harboe. 1985. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22:197-202.
25. Ovstebo, R., P. Brandtzaeg, B. Brusletto, K. B. Haug, K. Lande, E. A. Hoiby, and P. Kierulf. 2004. Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J. Clin. Microbiol. 42:2980-2987.
26. Pridmore, A. C., D. H. Wyllie, F. Abdillahi, L. Steeghs, P. van der Ley, S. K. Dower, and R. C. Read. 2001. A. lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2. J. Infect. Dis. 183:89-96.
27. Rosenqvist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
28. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-1782.
29. Sprang, T., A. S. Moller, A. Bjerre, E. Wedege, P. Kierulf, J. W. van der Meer, P. Brandtzaeg, M. van Deuren, and T. E. Mollnes. 2004. Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect. Immun. 72:3344-3349.
30. Sprong, T., N. Stikkelbroeck, P. van der Ley, L. Steeghs, L. van Alphen, N. Klein, M. G. Netea, J. W. van der Meer, and D. M. van Deuren. 2001. Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J. Leukoc. Biol. 70:283-288.
31. Sprong, T., P. van der Ley, L. Steeghs, W. J. Taw, T. J. Verver-Janssen, M. G. Netea, J. W. van der Meer, and M. van Deuren. 2002. Neisseria meningitidis can induce pro-inflammatory cytokine production via pathways independent from CD14 and Toll-like receptor 4. Eur. Cytokine Netw. 13:411-417.
32. Steeghs, L., H. de Cock, E. Evers, B. Zomer, J. Tommassen, and P. van der Ley. 2001. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J. 20:6937-6945.
33. Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der Ley. 1998. Meningitis bacterium is viable without endotoxin. Nature 392: 449-450.
34. Stephens, D. S., B. Greenwood, and P. Brandtzaeg. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210.
35. van Deuren, M., P. Brandtzaeg, and J. W. van der Meer. 2000. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin. Microbiol. Rev. 13:144-166.
36. van Deuren, M., J. van der Ven-Jongekrijg, A. K. Bartelink, R. van Dalen, R. W. Sauerwein, and J. W. van der Meer. 1995. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J. Infect. Dis. 172:433-439.
37. Waage, A., P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik. 1989. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169:333-338.
38. Waage, A., A. Halstensen, and T. Espevik. 1987. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357.
39. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4:133-142.